一 | New Delhi, Oct 13 (UNI) Congress leader Shashi Tharoor on Thursday said there were systematic flaws in the Congress presidential election process, even as he clarified he was not suggesting it was intentional.
The Thiruvananthapuram MP also indicated at differential treatment between him and Mallikarjun Kharge, who is being seen as the choice or the party leadership. Congress has maintained the party is not backing any candidate officially.
Addressing a press conference here, Tharoor said while he is not pointing fingers at Central Election Authority Chairman Madhusudan Mistry, there are flaws in the system.
"I am not saying anything against Mr. Mistry, there are some flaws in the systems which we all know. There have not been elections for 22 years..." said Tharoor.
He said there were discrepancies in the lists of voters provided.
"One list was given earlier, another list was given on Wednesday.... Some names were different in the lists, for some names, there was no phone number," he said.
"I am not saying it's being done intentionally. There have not been elections in our party for a long time. So there are issues. I know Mr. Mistry and his team are trying to hold free and fair elections. We are not complaining against them but there ar problems with the system," he said.
"That is why I used open mediums to take my message across. I am not sure I will be able to reach everyone before 17th."
He also pointed at differential treatment to candidates.
"Another issue is what some leaders did, that is why I said there is no level playing field. At a lot of places, big leaders, PCC chiefs welcome Kharge ji, call people for meetings. This happened for only one candidate, not for me," he said.
"Many times when I went to some PCC, the PCC chief became busy on the day...I am not complaining, but do you not see a difference in treatment?"
Election will be held on October 17, counting will be held on October 19 and results will be declared.
UNI AO BAV。 AI设计的口服减重药有望2028年底上市 
钱塘区生物医药产值已突破500亿元 近日，杭州德睿智药科技有限公司宣布完成累计5200万美元B轮融资。
二 | 2026年1月，杭州医药港，德睿智药一款名叫MDR-001的口服减重药，以令全球医药界瞩目的速度，启动Ⅲ期临床试验，成为国内首个进入临床Ⅲ期的AI小分子新药。
三 | 这家仅40多人的公司，把一款一类创新药从立项到推进至Ⅲ期临床的时间，压缩到了4.5年。
四 | 而传统同行完成同样的路程，通常需要8到12年。不用“大海捞针”了2021年初，85后海归博士牛张明，带着计算机和生物制药2个硕士学位、5种AI算法语言，在钱塘区成立了德睿智药。当时，他就想好了：“要走一条和传统制药完全不同的路。”传统新药研发有多难？业内有个“双十定律”，即成功研发一款创新药，平均需要10年的时间和10亿美元的投入。面对超过10的60次方级别、近乎无限的成药化学空间，科学家们只能靠经验和反复试错，如同在茫茫大海里捞针。
五 | 牛张明说：“过去的药物发现，靠大量实验、反复试错，不仅耗时间，成功率也低。现在用上AI，好比给每位科学家配了一个‘超级大脑’做助手。”2026年，德睿智药基于MDR-001的研发流程，搭建起了由多智能体驱动的全链条AI制药引擎MAP。这个平台覆盖靶点发现、分子设计、多目标优化、实验验证及临床试验全链条。
六 | “药物分子就像精密的拼图，每个片段都决定着药效和安全性。以往，这全靠科研人员的经验和反复试错。”牛张明解释，“MAP能通过学习海量已知药物的成功与失败案例，自动预测分子片段的性质，大幅减少试错成本、缩短研发周期。”他打了一个比方：“你可以把它想象成一位高效且永不疲倦的‘分子组装专家’，在虚拟世界里高速筛选，帮研发人员提前排除大量‘错误选项’。”药物研发，就这样从“大海捞针”变成了“高清导航”。口服减重新药将于2028年底上市MDR-001是一款GLP-1（胰高血糖素样肽-1）受体激动剂，与市面上常见的减肥注射剂最大的不同在于，它可以口服。“我们立项时，口服GLP-1还没有出现。口服小分子药物的依从性更高，患者不需要消毒针头注射、不需要低温冷藏保存，使用更方便；在某些适应证上疗效甚至优于注射剂型。”牛张明说。在MDR-001项目中，团队仅耗时8个月、实际仅合成80个小分子，就获得了高质量的临床前候选药物。从立项到推进至Ⅲ期临床研究，整体仅耗时4.5年，单产品累计研发投入控制在约2300万美元。对比传统同类药物的研发周期和投入，这组数字可以称得上是“奇迹”了。“从临床前阶段来看，AI制药平台可节省50%至70%的研发成本，并将研发周期缩短50%以上。”牛张明说。目前，MDR-001的Ⅲ期临床进展顺利，已在国内完成760名受试者招募，合作临床中心近50家。在已完成的IIb期临床试验中，317名平均体重约90公斤的受试者在用药24周后，体重平均降幅达10.3%，因不良反应导致的停药率仅为0.8%。如果一切顺利，这款“钱塘智造”的口服减重新药，有望于2028年底或2029年初上市。
Current article:http://mkl.yukujuankewazuhangfei.sbs/3ss3e/20260826/56572.html
Published on:12:07:59
